The global women’s health diagnostics market size was estimated at around USD 17.83 billion in 2022 and it is projected to hit around USD 36.27 billion by 2032, growing at a CAGR of 7.36% from 2023 to 2032. The women’s health diagnostics market in the United States was accounted for USD 7.4 billion in 2022.
Key Pointers
- North America led the market with the largest revenue share of 45% in 2022.
- Asia Pacific is anticipated to grow at the fastest CAGR of 8.35% from 2023 to 2032.
- By Application, the infectious diseases segment accounted for the highest revenue share of 53% in 2022.
- By Application, the prenatal segment is expected to expand at the fastest rate of 11.73% between 2023 to 2032.
- By End-use, the hospitals segment generated the maximum market share of 45% in 2022.
- By End-use, the homecare segment is predicted to grow at the noteworthy CAGR of 9.07% over the forecast period.
The women’s health diagnostics market represents a critical segment within the broader healthcare landscape, dedicated to addressing the distinct healthcare needs of women across various life stages. This market encompasses a wide array of diagnostic technologies, services, and products aimed at detecting, monitoring, and managing conditions specific to women’s health.
Market Growth
The growth of the women’s health diagnostics market is propelled by several key factors. Increasing awareness and prioritization of gender-specific health needs, coupled with a rising emphasis on preventive healthcare, are driving more women to seek diagnostic services. Technological advancements play a pivotal role, with continuous innovations in diagnostic imaging, in vitro diagnostics, and genetic testing enhancing the precision and efficiency of diagnostic procedures. The integration of advanced technologies, such as molecular diagnostics and point-of-care testing, further contributes to the market’s expansion. Collaborative efforts between healthcare professionals, researchers, and industry stakeholders foster the development of novel diagnostic solutions. Additionally, the market benefits from a holistic approach to women’s health, incorporating comprehensive disease-specific diagnostics tailored for conditions such as breast and gynecological cancers. As these growth factors converge, the women’s health diagnostics market is positioned to advance, providing women with improved access to accurate and timely diagnostic interventions for better overall health outcomes.
Get a Sample:https://www.visionresearchreports.com/report/sample/40943
Report Scope of the Women’s Health Diagnostics Market
| Report Coverage | Details |
| Market Revenue by 2032 | USD 36.27 billion |
| Growth Rate from 2023 to 2032 | CAGR of 7.36% |
| Revenue Share of North America in 2022 | 45% |
| CAGR of Asia Pacific from 2023 to 2032 | 8.35% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Read More: https://www.heathcareinsights.com/fluorescent-in-situ-hybridization-probe-market/
Market Dynamics
Drivers
Increasing Awareness and Prioritization:
The women’s health diagnostics market is driven by a growing awareness of gender-specific health issues and an increasing prioritization of women’s healthcare needs. As awareness spreads, more women actively seek diagnostic services.
Evolution of In Vitro Diagnostics (IVD):
In Vitro Diagnostics (IVD) plays a crucial role in women’s health diagnostics, with continuous advancements in this field leading to quicker and more accurate test results. The evolution of IVD technologies contributes to improved diagnostic precision.
Restraints
Lack of Healthcare Infrastructure:
In some regions, a lack of adequate healthcare infrastructure poses a challenge to the women’s health diagnostics market. Insufficient diagnostic facilities and healthcare resources can impede timely and comprehensive diagnostic interventions.
Resistance to Behavioral Change:
Resistance to behavioral change and a reluctance to engage in proactive healthcare practices can hinder the uptake of women’s health diagnostic services. Encouraging a shift towards preventive healthcare is a complex challenge in certain demographics.
Opportunities
Expanding Telehealth and Remote Monitoring:
The increasing adoption of telehealth and remote monitoring presents a significant opportunity for the women’s health diagnostics market. Remote diagnostic services enhance accessibility, especially in underserved areas, and facilitate continuous monitoring of women’s health.
Digital Health Platforms and Apps:
The proliferation of digital health platforms and mobile apps provides opportunities for enhancing women’s health diagnostics. These platforms can offer educational resources, symptom tracking, and personalized health recommendations, fostering proactive healthcare behaviors.
Application Insights
The infectious diseases segment accounted for the largest revenue share of 53% in 2022. The global emergence of SARS, H1N1, Ebola, and COVID-19 have negatively impacted women, specifically their sexual and reproductive health. According to the National Centre for Biotechnology Information, STDs. was the cause of 50% of avoidable infertility in the U.S. Additionally, the majority of STDs can be transmitted to an unborn child or fetus, occasionally with catastrophic results. In addition, the findings indicate that women are more likely to develop active Mycobacterium TB illness.
The prenatal segment is expected to grow at the fastest rate of 11.73% during the forecast period. The infectious diseases that the mother has is transmitted to the unborn child or fetus, which is driving the growth of this segment. According to the National Centre for Biotechnology Information, 20,000 babies are born to hepatitis B virus (HBV) infected mothers in the U.S. 6,000 of these infants would develop chronic HBV infections without postexposure prophylaxis, and 1,500 would succumb to chronic liver disease before their time.
End-use Insights
The hospitals segment contributed the largest market share of 45% in 2022, as they are the first choice as the diagnostic center for women for the detection of cancer, infectious disease, osteoporosis, pregnancy & fertility tests. In March 2021, iCad announced The U.S. Food and Drug Administration (FDA) approval of ProFound A.I. Version 3.0 for Digital Breast Tomosynthesis (DBT). It is a deep learning, high-performance workflow solution that helps in detecting malignant soft tissue calcifications and densities.
The homecare segment is anticipated to grow at the noteworthy CAGR of 9.07% over the forecast period owing to increasing investments by market players to commercialize portable and point-of-care devices. Furthermore, growing awareness about home diagnostic devices is estimated to spur the growth of the segment. Yeast infections of the vagina and urinary tract, menopause, colon cancer, breast cancer, and fertility are the diseases for which self-diagnosis devices/kits are used by women. In October 2018, the FDA approved the PicoAMH Elisa by Ansh Labs, a self-diagnosis menopause kit.
Regional Insights
North America dominated the market with the largest revenue share of 45% in 2022. This can be attributed to the high adoption of technologically advanced products, product launches, and government initiatives.
National Women’s Health Week (NWHW) begins on 14th May – 20th May every year and The FDA Office of Women’s Health (OWH) theme for NWHW 2023 was to encourage women to #KNOWHmore About Your Health, Today and Every Day. In May 2019, Bayer launched a campaign “Test Your Cancer” to help cancer patients understand that genomic testing is a very important step in diagnosis thereby getting a real picture of individual cancer.
In May 2023 SOPHiA GENETICS announced that a private molecular laboratory, Natural State Laboratories, chose the former’s technology to expand their research capabilities and cancer testing. Natural State Laboratories is expected to start using SOPHiA DDM for in-house hereditary cancer testing.
Asia Pacific is expected to grow at the fastest CAGR of 8.35% during the forecast period. Improving healthcare infrastructure, awareness about women’s health disorders, government initiatives, and increased participation of women in the workforce are some of the factors poised to positively impact regional market growth. In November 2016, the Indian government launched the Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) scheme to provide free health checkups to pregnant women. Under this scheme, women would be tested for anemia, high blood sugar (gestational diabetes); blood pressure, and hormonal disorders, and have access to free ultrasounds to track the health and development of a fetus.
Key Companies
- F. Hoffmann-la Roche Ltd.
- Siemens Aktiengesellschaft
- Quest Diagnostics Incorporated
- Ge Healthcare
- Koninklijke Philips N.V.
- Abbott Laboratories
- Becton, Dickinson, and Company,
- Hologic, Inc
Women’s Health Diagnostics Market Report Segmentations:
By Application
- Cancer
- Infectious disease
- Osteoporosis
- Pregnancy & fertility
- Prenatal
By End-use
- Hospitals
- Laboratory
- Home Care
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/40943
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308